HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target

HC Wainwright & Co. analyst Brandon Folkes has reiterated a 'Buy' rating on Sagimet Biosciences (NASDAQ: SGMT) and maintained a price target of $29 for the stock.